AEGiS-GMHC: Crixivan Warning: Keep to Three Times a Day

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Crixivan Warning: Keep to Three Times a Day

GMHC Treatment Issues, Vol. 12, No. 9 - September 20, 1998
Dave Gilden

On September 18, Merck & Co. publicly warned against taking its protease inhibitor indinavir (Crixivan) on a twice-daily dosing schedule of 1200 mg every 12 hours. The standard schedule is 800 mg three times a day, but many doctors have been converting their patients to the much easier twice-a-day administration after Merck last winter announced results of an initial pilot study of twice-daily dosing. In that study, which observed 28 volunteers for 32 weeks, 1200 mg of indinavir twice a day appeared just as active against HIV as 800 mg three times a day.

Starting last November, Merck recruited 635 volunteers without prior treatment to compare AZT/3TC plus either twice-daily or thrice-daily indinavir. For the 87 participants now out to 24 weeks, the picture is different than the first time around. Ninety-one percent on the standard regimen had viral loads under 400 compared to only 64% on the twice-daily regimen.

The pilot study results were received with skepticism because their preliminary nature said little about the durability of the response to indinavir twice a day. Many experts could not believe that this new dosing schedule would be as good as the old one. It seemed obvious that the trough blood levels of indinavir, reached at the six-hour point between doses, would be much lower than with the every eight hour, thrice-daily schedule. This would give HIV a window of opportunity to reproduce and evolve into drug-resistant strains.

While canceling the trials of twice-daily indinavir, Merck is continuing to test twice-daily indinavir combined with either ritonavir or nelfinavir. Both of these protease inhibitors have the side effect of reducing indinavir's breakdown by the liver. The result is to make indinavir more stable in the body and give a twice-daily schedule a better rationale.

980920
GM120905

Copyright © 1998 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .